Bristol-Myers Squibb Company (BMY) Q3 2023 Earnings Results

Bristol Myers Squibb Beats on EPS, Stock Down 6.43%

Bristol Myers Squibb's earnings report showed a positive surprise on EPS, indicating stronger-than-expected profitability. However, the stock fell by 6.43%, likely due to a lack of revenue details and no guidance for the future. Investors may be concerned about market conditions and the company's ability to navigate them.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$2.00	N/A	+13.64%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed a cautious optimism about future growth despite current market pressures. They emphasized their commitment to innovation and addressing challenges head-on.

Management highlighted the continued strength of their pipeline.

They acknowledged challenges in the market but remain focused on long-term goals.

Bristol Myers Squibb Beats on EPS, Stock Down 6.43%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Beats on EPS, Stock Down 6.43%

Key numbers

Management commentary